Technologies

Developing Drugs that Patients Can Live With

Facing cancer is a frightening and confusing time for patients. All too often, treatment brings with it debilitating side effects that compromise the patient’s ability to engage in activities that bring value to their life—without any guarantee that the treatment will succeed. We are committed to changing that by providing personalized cancer therapies that destroy the tumor while protecting the health and dignity of the patient.

Personalizing cancer therapy is a multidisciplinary pursuit based on a variety of interdependent product development programs. Our scientists are advancing these programs through close collaboration and the integration of powerful technologies that will help us achieve our goal of hurting the cancer more than the patient. These technologies include:

• Our polyglutamate delivery technology may open the way to the selective delivery of cancer therapies to tumor tissue, potentially reducing the toxic side effects of widely used and well-characterized therapies. More
• Our Genetic Polymer^™ technology supports the need for new rDNA-derived protein-based drugs by potentially extending plasma half-life. This could reduce the time and cost of developing new drugs, so patients can benefit sooner from breakthrough scientific discoveries. More
• Our advanced systems biology platform addresses context of vulnerability. Every tumor and every patient has a specific set of genomic and clinical characteristics. Potentially, these characteristics can be used in synchrony to accelerate drug development and identify patients who will respond to treatment. More